Clinical trials: Rhinitis, Allergic, Perennial
Rhinitis, Allergic, Perennial
Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06332)
This is a multicenter, randomized, parallel design, double-blind study of mometasone furoate (MF) in pediatric subjects with perennial allergic rhinitis.
- Trial name
- NCT01135134
- Testing
- Mometasone furoate
- Volunteers
- 333 people
- Sponsor
- Organon and Co
Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis
Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03180)
This was a crossover study designed to see if patients with allergy symptoms preferred Clarinex® or Zyrtec®. Patients were randomized to take 7 days of Clarinex or Zyrtec treatment, followed by a 5 to 28-day washout period (days…
- Trial name
- NCT00794846
- Testing
- Desloratadine 5 mg (Clarinex), Cetirizine (Zyrtec)
- Volunteers
- 124 people
- Sponsor
- Organon and Co
Rhinitis, Allergic, Perennial
Clinical Study, Non Inferiority Between Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Rhinitis
This study is to evaluate non inferiority of Eurofarma budesonide nasal spray x referral Astrazeneca budesonide. Half patients will receive Eurofarma medication and half patients will receive Astrazeneca medication.
- Trial name
- RINEX50 (NCT02988778)
- Testing
- Budesonid 50mcg (Noex), Budesonid 50mcg (Busonid)
- Where
- Brazil
- Sponsor
- Eurofarma Laboratorios S.A.
Rhinitis, Allergic, Perennial
Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)
The primary objective of this study is to evaluate the efficacy of the concomitant administration of ciclesonide nasal spray and azelastine nasal spray versus ciclesonide nasal spray alone in patients (18 years or older) with…
- Trial name
- NCT00806754
- Testing
- Ciclesonide nasal spray + Azelastine
- Where
- 35 sites in United States
- Volunteers
- 340 people
- Sponsor
- AstraZeneca
Rhinitis, Allergic, Perennial
A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).
The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with…
- Trial name
- NCT00103454
- Testing
- GW685698X
- Where
- 49 sites in United States, Canada
- Volunteers
- 288 people
- Sponsor
- GlaxoSmithKline
Allergic Rhinoconjunctivitis, Perennial Allergic Rhinitis
Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis
Prospective, randomized, placebo-controlled, multicenter of 3 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with mild to moderate…
- Conditions
- Allergic Rhinoconjunctivitis, Perennial Allergic Rhinitis, House Dust Mite Allergy, Pollen Allergy
- Trial name
- NCT04874714
- Testing
- MM09-MG01(30.000-30.000), MG01(30.000), MM09(30.000)
- Where
- 13 sites in Spain
- Volunteers
- 18 people
- Sponsor
- Inmunotek S.L.
Perennial Allergic Rhinitis
Trial of JYB1904 Injection in Patients With Perennial Allergic Rhinitis
This Phase II Trial is Meant to Evaluate the Efficacy, and Safety of JYB1904 Injection in Patients With Perennial Allergic Rhinitis.
- Trial name
- NCT07459452
- Testing
- JYB1904
- Volunteers
- 135 people
- Sponsor
- Jemincare
Rhinitis, Allergic, Perennial
Single Dosing Clinical Trial of HL151
The purpose of this study is to assess the pharmacokinetic characteristics of bepotastine after single oral administration of TALION tab, a IR formulation of bepotastine as reference drug and HL151, a SR formulation of…
- Trial name
- NCT02682745
- Testing
- HL151, TALION tab.
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hanlim Pharm. Co., Ltd.
Perennial Allergic Rhinitis, PAR
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of ciclesonide nasal aerosol administered once daily to male and premenarchal female subjects 6 to 11 years…
- Trial name
- NCT01451541
- Testing
- Ciclesonide nasal aerosol 37 mcg, ciclesonide nasal aerosol 74 mcg
- Where
- 60 sites in United States
- Volunteers
- 848 people
- Sponsor
- Sumitomo Pharma America, Inc.
Rhinitis, Allergic, Perennial and Seasonal
A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR)
This study will be a randomised, double blind, placebo controlled, 3-way, incomplete block crossover study to evaluate the effect of single and repeat doses of levocabastine, FF, placebo and a FDC of FF/levocabastine…
- Trial name
- NCT01957202
- Testing
- FF/levocabastine, FF, levocabastine
- Where
- Austria
- Volunteers
- 71 people
- Sponsor
- GlaxoSmithKline
Perennial Allergic Rhinitis
Investigation of the Effects of a Multispecies Probiotic Formulation on Perennial Allergic Rhinitis
The goal of this clinical trial is to learn if a probiotic formulation consisting of multiple bacterial strains has a positive effect on the quality of life of participants with chronic perennial allergic rhinitis symptoms.
- Trial name
- AllerGo (NCT07157462)
- Testing
- Multi-species probiotic powder for oral solution. Dietary supplement containing six bacterial strains (Lactobacillus and Bifidobacterium species)
- Where
- France
- Volunteers
- 97 people
- Sponsor
- Winclove B.V.
Common Cold, Allergy
Symbiofilm Trial in Allergic Kids (SYMBIOFILM-TAK)
Healsea® Children is a seawater-based nasal spray supplemented with a natural Symbiofilm® extract (0.02%) isolated from marine bacteria.
- Trial name
- NCT05034328
- Testing
- Healsea® Children, Conventional therapies for common cold
- Where
- 15 sites in Poland
- Volunteers
- 186 people
- Sponsor
- Lallemand Pharma AG
Perennial Allergic Rhinitis
The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis
The objectives of this study are: to confirm the superiority of TAU-284 over placebo after two weeks of administration to pediatric patients with perennial allergic rhinitis and to investigate safety of TAU-284.
- Trial name
- NCT01861522
- Testing
- Bepotastine besilate
- Where
- 2 sites in Japan
- Volunteers
- 473 people
- Sponsor
- Tanabe Pharma Corporation
Perennial Allergic Rhinitis
Children, Perennial Allergic Rhinitis (PAR), l-t Growth
The purpose of this study is to compare the effect of Rhinocort nasal spray with placebo on growth in children with perennial allergic rhinitis over 12 months.
- Trial name
- NCT00641212
- Testing
- Budesonide
- Volunteers
- 209 people
- Sponsor
- AstraZeneca
Rhinitis, Allergic, Perennial, House Dust Mite Allergy
Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR
The objective of this study was to assess the efficacy and safety of 12 months of treatment with 300 IR of STG320 sublingual tablets compared with placebo in adults and adolescents with HDM-associated allergic rhinitis.
- Trial name
- NCT02443805
- Testing
- 300 IR
- Where
- 2 sites in United States, France
- Volunteers
- 1,607 people
- Sponsor
- Stallergenes Greer
Rhinitis, Allergic, Seasonal
Study Of Perennial Allergic Rhinitis
This study was designed to assess safety of an investigational nasal spray in the treatment of perennial allergic rhinitis. Perennial allergic rhinitis is triggered by house dust, mite and mold etc.
- Trial name
- NCT00358475
- Testing
- GW685698
- Volunteers
- 65 people
- Sponsor
- GlaxoSmithKline
Rhinitis Perennial
Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Perennial Allergic Rhinitis (PAR)
Primary Objective: To evaluate safety (4 weeks) Secondary Objectives: To evaluate the long-term safety (12 weeks) To evaluate the efficacy To characterize the pharmacokinetic profile
- Trial name
- NCT01244217
- Testing
- fexofenadine/Allegra (M016455)
- Where
- 15 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Sanofi
Perennial Allergic Rhinitis
Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis
This is an open-label, randomized, multicenter, 2-way crossover study in subjects 12 years or older with perennial allergic rhinitis (PAR) to evaluate the psychometric properties of a novel-patient administered assessment of…
- Trial name
- NCT01287364
- Testing
- ciclesonide hydrofluoroalkane (HFA) nasal aerosol, mometasone nasal inhalation
- Where
- 6 sites in United States
- Volunteers
- 185 people
- Sponsor
- Sumitomo Pharma America, Inc.
Rhinitis, Allergic, Perennial
Cetirizine Placebo Controlled Study For Perennial Allergic Rhinitis
Study objective is to verify the superiority of CTZ DS to the placebo groups in the change of total nasal symptom score (TNSS) over the total treatment period from the score of the baseline assessment period.
- Trial name
- NCT00490204
- Testing
- Cetirizine
- Where
- 28 sites in Japan
- Volunteers
- 239 people
- Sponsor
- GlaxoSmithKline
Allergic Rhinitis
Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR)
The purpose of this study is to compare the effect of 6 weeks of treatment with beclomethasone dipropionate (BDP) nasal aerosol versus placebo on HPA-axis function, as assessed by 24-hour serum cortisol weighted mean, and to…
- Trial name
- NCT01697956
- Testing
- BDP
- Where
- 6 sites in United States
- Volunteers
- 99 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.